Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Knight Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was C$880.4 Mil.
Knight Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$32.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics EV-to-EBIT Related Terms
Knight Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's EV-to-EBIT falls into.
Knight Therapeutics's current Enterprise Value is C$846.3 Mil.
Knight Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$32.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (TSX:GUD) has a EV-to-EBIT of 26.09 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Knight Therapeutics and its competitors. According to the industry distribution chart, Knight Therapeutics ranks #465 out of 681 companies in the Drug Manufacturers industry, placing it in the top 68.3%.
Is Knight Therapeutics' EV-to-EBIT too high?
Knight Therapeutics' current EV-to-EBIT is 26.09. The Drug Manufacturers industry median EV-to-EBIT is 15.99. Knight Therapeutics' value of 26.09 is 63.2% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #465 out of 681 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #465 out of 681 companies for EV-to-EBIT. This places Knight Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.99. Knight Therapeutics' value of 26.09 is 63.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current EV-to-EBIT of 26.09 is 63.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current EV-to-EBIT is 26.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Fairly Valued. The stock's GF Value™ is C$9.19, compared to a current price of C$9.50 — trading 3.4% above its estimated fair value. The current EV-to-EBIT is 26.09 and 63.2% above the Drug Manufacturers industry median of 15.99. Knight Therapeutics' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current EV-to-EBIT is 26.09 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of C$9.50 is trading 3.4% above its estimated GF Value™ of C$9.19.
GuruFocus considers Knight Therapeutics to be Fairly Valued.
Key valuation signals for TSX:GUD:
EV-to-EBIT: 26.09
GF Value™: C$9.19 vs. price of C$9.50 (3.4% above fair value)
Industry Position: 63.2% above the Drug Manufacturers median (#465 of 681)
No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
77GF Score
Get the complete analysis for TSX:GUD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:GUD has been successfully added to your 
